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examinations, treatment, hospital visits, and complications. The productivity costs included time taken for consultation and treatment, and expenses for travel to appointments for women and their companions. The resource use data were from questionnaires completed by the trial participants. The unit costs were from national sources and published studies, using itemised costs for the UK. Published average wages were used for the productivity costs. The price year was 2004 and costs were converted to 2004, using the hospital and community health services pay and price index. All costs were presented in UK pounds sterling (£) and they were discounted at an annual rate of 3.5%.
Analysis of uncertainty:
Monte Carlo simulation was performed to investigate the impact of parameter uncertainty on the cost-effectiveness ratios.
Results
The strategy of colposcopy plus biopsy and recall was associated with the highest mean discounted QALYs at 2.181, followed by colposcopy plus immediate treatment at 2.149, and cytological surveillance at 2.129.
The mean discounted costs to the NHS were £241.1 with colposcopy plus biopsy and recall, £240.3 with colposcopy plus immediate treatment, and £150.2 with cytological surveillance. The costs to society were £327.5 with colposcopy plus biopsy and recall, £339.9 with colposcopy plus immediate treatment, and £204.4 with cytological surveillance.
From the NHS perspective, the incremental cost-effectiveness ratio (ICER) was £4,546 per QALY gained for immediate treatment versus surveillance and £26 per QALY gained for biopsy and recall versus immediate treatment. From the societal perspective, immediate treatment was dominated as it was more expensive and less effective than biopsy and recall. The cost per QALY gained for biopsy and recall versus surveillance was £2,373.
The results of the Monte Carlo simulation indicated that the 95% confidence intervals for the ICERs were very wide. For example, for the societal ICER of £2,373, the 95% confidence interval was -£24,651 to £25,770.
